Biomanufacturing company Multiply Labs is using Nvidia technologies to develop robotic biomanufacturing systems for ...
To evaluate the potential for applying GMP-ready robotic systems to commercial-scale cell therapy manufacturing.
SAN FRANCISCO--(BUSINESS WIRE)--Multiply Labs, a leader in robotic biomanufacturing, today announced a landmark milestone in its mission to scale production of cell and gene therapies; The company is ...
Collaboration with AstraZeneca will focus on scaling cell therapy manufacturing using GMP-ready end-to-end robotic ...
Multiply Labs' goal is to enable scalable, high-throughput manufacturing while maintaining rigorous quality and regulatory standards.
Breakthrough partnership with Universal Robots transforms "artisanal" manufacturing, making personalized, life-saving cancer treatments affordable and widely available. Leveraging collaborative robots ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results